6.81
+0.42(+6.57%)
Currency In USD
Address
245 Main Street
Cambridge, MA 02142
United States of America
Phone
617 500 8080
Website
Sector
Healthcare
Industry
Biotechnology
Employees
54
First IPO Date
July 30, 2021
| Name | Title | Pay | Year Born |
| Benjamin J. Zeskind | Co-Founder, President, Chief Executive Officer & Director | 941,316 | 1982 |
| Robert J. Carpenter | Co-Founder & Chair Emeritus | 45,000 | 1946 |
| Harold E. Brakewood | Chief Business Officer | 579,769 | 1966 |
| Michael D. Bookman | Chief Legal Officer & Secretary | 689,959 | 1987 |
| Brett Hall | Chief Scientific Officer | 918,124 | 1968 |
| Peter King | Head of Discovery & Vice President | 0 | N/A |
| Praveen Nair | Head of Translational Pharmacology & Vice President | 0 | N/A |
| Leah R. Neufeld | Chief People Officer | 0 | 1972 |
| Mallory Morales | Principal Financial & Accounting Officer, Chief Accounting Officer and Treasurer | 0 | 1983 |
| Paula George | Director of Accounting & Operations and Assistant Corporation Controller | 0 | N/A |
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.